NuCana (NCNA) Depreciation & Amortization (CF) (2017 - 2025)
NuCana (NCNA) reported Depreciation & Amortization (CF) of $91781.5 for Q4 2025, down 37.82% on a YoY basis from $147602.7 in Q4 2024, and down 1.42% sequentially from $93106.0 in Q3 2025.
NuCana (NCNA) Depreciation & Amortization (CF) (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $91781.5 in Q4 2025.
- For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 37.82% year-over-year to $91781.5; the trailing twelve-month figure through Dec 2025 stood at $184887.5 (down 72.29% YoY), and the FY2025 full-year result was $361271.8, down 45.86% from the prior year.
- Depreciation & Amortization (CF) eased to $91781.5 in Q4 2025, from $93106.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $362614.9 in Q4 2021 to a low of $91781.5 in Q4 2025.
- A 5-year average of $216883.8 and a median of $178426.6 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) advanced 23.15% in 2021 and slumped 47.22% in 2023, its largest moves.
- Tracing NCNA's Depreciation & Amortization (CF) over 5 years: stood at $362614.9 in 2021, then retreated by 5.19% to $343792.8 in 2022, then tumbled by 49.1% to $175002.4 in 2023, then fell by 15.66% to $147602.7 in 2024, then sank by 37.82% to $91781.5 in 2025.
- Business Quant data shows NCNA's Depreciation & Amortization (CF) at $91781.5 in Q4 2025, $93106.0 in Q3 2025, and $147602.7 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 91,781.47 |
| Dec 31, 2025 | 91,781.47 |
| Sep 30, 2025 | 93,105.99 |
| Sep 30, 2025 | 93,105.99 |
| Dec 31, 2024 | 147,602.71 |
| Dec 31, 2024 | 147,602.71 |
| Sep 30, 2024 | 175,405.52 |
| Sep 30, 2024 | 175,405.52 |
| Jun 30, 2024 | 171,662.02 |
| Jun 30, 2024 | 171,662.02 |
| Mar 31, 2024 | 172,518.47 |
| Mar 31, 2024 | 172,518.47 |
| Dec 31, 2023 | 175,002.42 |
| Dec 31, 2023 | 175,002.42 |
| Sep 30, 2023 | 184,935.98 |
| Sep 30, 2023 | 184,935.98 |
| Jun 30, 2023 | 181,447.66 |
| Jun 30, 2023 | 181,447.66 |
| Mar 31, 2023 | 173,817.86 |
| Mar 31, 2023 | 173,817.86 |